1 hour ago
Mankind Pharma reported a 30% year-on-year rise in first-quarter net profit, driven by steady revenue growth and improved operating margins, as strong performance in its domestic chronic business and a rebound in acute therapies offset slower growth in consumer healthcare.
2 Min Read
Pharmaceutical company Mankind Pharma reported a 30% year-on-year increase in net profit for the first quarter of FY27 on Thursday, July 30, supported by steady revenue growth and improved operating margins.
The company posted a net profit of ₹568 crore for the quarter ended June 30, compared with ₹438 crore in the corresponding period last year. Revenue from operations rose 13% year-on-year to ₹4,031 crore from ₹3,570 crore.
Operating performance also improved during the quarter. EBITDA increased 25% year-on-year to ₹1,057 crore from ₹847 crore, while EBITDA margin expanded to 26.2% from 23.7% a year earlier.
Domestic business remains strong
Commenting on the performance, Vice Chairman and Managing Director Rajeev Juneja said the company's overall domestic business, excluding the consumer healthcare business, grew 11% during the quarter. Growth was led by the domestic business, where the chronic portfolio grew 15.8%, including 19.4% growth in the cardiac segment and 12.7% growth in anti-diabetes therapies.
The company also reported growth recovery in its acute business, driven by the gastro, VMN and gynaecology segments, along with strong double-digit growth in the BSV domestic specialty business.
The over-the-counter (OTC) business grew around 4% during the quarter, while the international business recorded 29% year-on-year growth.
Juneja said disciplined execution and strengthening business fundamentals resulted in improvements across key operating and financial metrics during the quarter, laying the foundation for long-term sustainable growth.
Consumer healthcare performance
In the consumer healthcare business, revenue grew 4% year-on-year, partly impacted by the base effect of the discontinued cash-and-carry business. Despite the softer growth, the company said it gained market share in key brands, including Manforce, Prega News and Gas-O-Fast.
The company said the contribution of modern trade and e-commerce increased to 15% in the first quarter from 11% a year ago, supported by 38% growth. Secondary sales of Gas-O-Fast and Ova News grew 10% and 36% year-on-year, respectively.
business update
Mankind Pharma's international business reported 29% revenue growth during the quarter. Excluding BSV, the company launched one new product in the US during Q1FY27, taking the total number of products launched in the market to 49.
Shares of Mankind Pharma Ltd. ended 0.88% lower at ₹2,569.90 on the NSE on Thursday after the company reported its June quarter earnings. The stock declined ₹22.80 during the session despite the company reporting a 30% year-on-year rise in net profit and a 13% increase in revenue.
